ARGX vs. MRNA: argenx vs. Moderna Stock Comparison

Company Profile

argenx (ARGX) and Moderna (MRNA) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Moderna (MRNA) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Moderna (MRNA) is heavily traded at around 21.61M shares per day, whereas argenx (ARGX) sees a more moderate 359.84K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

argenx (ARGX) has no ROE value reported for this period; Moderna (MRNA) reports a negative figure of -39.00%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.

Moderna (MRNA) reports a negative net margin of -141.43%, usually indicating a net loss over the period. Meanwhile argenx (ARGX) reports 31.73%, ranking against industry peers normally.

Moderna (MRNA) reports a negative operating margin of -557.93%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile argenx (ARGX) reports 36.27%, ranking against industry peers normally.

Profitability Metrics

Growth

argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Moderna (MRNA) at -39.92% is in the bottom quartile, showing a clear gap in revenue momentum.

Only one side can be read here: argenx (ARGX) reports EPS growth of 53.13%, ranked against its industry; Moderna (MRNA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Short-term liquidity can only be read on one side of this pairing: Moderna (MRNA) shows current ratio of 2.30 against its industry benchmark, while argenx (ARGX) has no reading this period.

argenx (ARGX) at 0.01 keeps leverage in the lower industry quartile, while Moderna (MRNA) at 0.19 runs a more typical debt-to-equity mix.

Financial Strength Metrics

Dividends

Neither argenx (ARGX) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither argenx (ARGX) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: argenx (ARGX) trades at 32.12 times trailing earnings, ranked against its peers, while Moderna (MRNA) has no P/E ratio this period.

argenx (ARGX) at 9.86 is priced about in line with its industry on P/S ratio, while Moderna (MRNA) at 45.55 sits in the pricier quartile — MRNA costs more per dollar of sales.

Both look rich against book: Moderna (MRNA) at 11.58 sits in the upper P/B ratio quartile, and argenx (ARGX) at 172.23 prices even higher, above its industry range.

Valuation Metrics